Boston Scientific Says Dead-End SEC Probe Sinks Stock Suit
The U.S. Securities and Exchange Commission is not bringing securities claims against Boston Scientific for halting the production of its Lotus Edge heart device, the company said Monday as it sought...To view the full article, register now.
Already a subscriber? Click here to view full article